ESTEVE
SpecialtyESTEVE is a specialty pharmaceutical company focused on Oncology. Key products include QUZYTTIR.
ESTEVE's Key Drugs
ESTEVE's core commercial portfolio centers on QUZYTTIR, spanning Oncology — its most strategically important drugs approved in the last 15 years.
ESTEVE's Recent FDA Approvals
New NDA/BLA approvals for ESTEVE over the last two years — novel drugs only, excluding generics and label supplements.
ESTEVE's Therapeutic Areas
ESTEVE's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ESTEVE's Top Competitors
ESTEVE's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ESTEVE Pipeline Snapshot
Active clinical trials for ESTEVE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • QUZYTTIR leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1961-12-04
- Latest
- 2025-07-28
- Applications
- 4